Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14717193 | 1.00 | DAGLA (0.37) | DAGLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14717195 | 1.00 | DAGLA (0.37) | DAGLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14733667 | 0.89 | PPARG (0.35) | DAGLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14717440 | 0.75 | DAGLA (0.38) | DAGLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14717438 | 0.75 | DAGLA (0.38) | DAGLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14732888 | 0.75 | DAGLA (0.40) | DAGLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14718098 | 0.74 | SLC22A12 (0.43) | CYP3A4CYP2C19SLC22A12MMENAMPT | |
| SCHEMBL14718100 | 0.74 | SLC22A12 (0.43) | CYP3A4CYP2C19SLC22A12MMENAMPT | |
| SCHEMBL14718097 | 0.74 | SLC22A12 (0.43) | CYP3A4CYP2C19SLC22A12MMENAMPT | |
| SCHEMBL14718102 | 0.74 | SLC22A12 (0.43) | CYP3A4CYP2C19SLC22A12MMENAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940722-B2 | Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2015-01-27 | — | — | US | disclosed |
| EP-2542537-B1 | NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE | PHENEX PHARMACEUTICALS AG (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-20130053380-A1 | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053380-A1 | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | RORB, RORC, RORA | DAGLA 4550/4885CYP3A4 583/4885CYP2D6 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.